Malaria is caused by the infection of human red blood cells by *Plasmodium* spp. and is transmitted through mosquitoes as vector. Five species of *Plasmodium* are known to be infectious to humans \[[@b1-kjp-58-1-61]\]. According to 2018 World Malaria Report, 2.4 billion people worldwide are exposed to the malaria infection, and more than 219 million are infected annually, with about 435,000 deaths \[[@b2-kjp-58-1-61]\]. According to the disease web statistics system of the Korea Centers for Disease Control and Prevention (KCDC), 33,115 malaria cases have been reported between 1993 and 2016, and 3.2% of them were imported. In last 10 years (2005--2016), most of the malaria were influxed from Africa (63.7%) and followed by Asia (33.3%). species of the imported malaria was *P. falciparum* (50.4%), *P. vivax* (28.7%), *P. ovale* (3.0%), and *P. malariae* (1.1%) \[[@b3-kjp-58-1-61]\]. Three cases of ovale malaria were reported between 2005 and 2012, all of which occurred in patients who had visited West Africa (Cote d'Ivoire and Ghana) \[[@b4-kjp-58-1-61]--[@b6-kjp-58-1-61]\]. Malariae malaria has also been reported in 2 patients who had been infected in West Africa (Guinea and Ghana) in 2011 and 2013, respectively \[[@b7-kjp-58-1-61],[@b8-kjp-58-1-61]\].

According to the World Malaria Report 2018 \[[@b2-kjp-58-1-61]\], it is reported that most cases of falciparum malaria occurring in Africa, and recently, the spread of ovale malaria from Africa has also increasing. Occurrence of ovale malaria has been increasingly reported in people returning from Africa in Henan, Shandong, and Jiangsu provinces in China \[[@b9-kjp-58-1-61]--[@b11-kjp-58-1-61]\].

In this study, we report the diagnosis and genetic analysis of *P. ovale* imported from West and South Africa between 2013 and 2016. Six patients (4 males and 2 females; 25--57 years old) infected with *P. ovale* were collected for this study ([Table 1](#t1-kjp-58-1-61){ref-type="table"}). The patients had recently visited Equatorial Guinea, Angola, Cameroon, Zambia, or Uganda for missionary activity or business trips. According to the US CDC's Yellow Book \[[@b12-kjp-58-1-61]\], malaria with chloroquine resistance have been reported in all these countries. *P. ovale* represents 5 to 15% of all *Plasmodium* spp. in these countries.

Microscopic examination with Wright-Giemsa staining revealed that the parasites were morphologically similar to *P. vivax*; the infected RBCs were slightly enlarged and oval in shape with fimbriated edges characteristic of *P. ovale* ([Fig. 1](#f1-kjp-58-1-61){ref-type="fig"}). The results of the rapid diagnostic test (RDT) and SD Bioline Malaria Antigen P.f/Pan rapid kits were negative in all patients. A recent report shows that PCR testing is also necessary due to the low sensitivity of ovale malaria RDT testing \[[@b13-kjp-58-1-61]\]. Thus, nested polymerase chain reaction (PCR) targeting 18S rRNA genes was performed for molecular discrimination of *Plasmodium* spp., as previously described by Snounou et al. \[[@b14-kjp-58-1-61]\].

Genomic DNAs of ovale malaria patients were extracted from blood samples using the QIAamp DNA Blood Mini kit (Qiagen, Valencia, California, USA). As described by Snounou et al. \[[@b14-kjp-58-1-61]\], namely, the *Plasmodium* specific primer (rPLU5/rPLU6) was used for the first-round PCR and ovale specific primer (rOVA1/rOVA2) were used for the second-round PCR. Thermal cycling was performed with the following parameters: 1st PCR: pre-denaturation at 95°C for 1 min, denaturation at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min (35 cycles); and final extension at 72°C for 10 min; 2nd PCR: pre-denaturation at 95°C for 5 min, denaturation at 95°C for 1 min, annealing at 60°C for 30 sec, and extension at 72°C for 30 sec (35 cycles); and final extension at 72°C for 10 min. The amplified DNA products corresponding to *P. ovale* (800 bp) were visualized on a 1.5% agarose gel stained ethidium bromide ([Fig. 2](#f2-kjp-58-1-61){ref-type="fig"}). The PCR products were sequenced by Macrogen Inc. (Seoul, Korea). The Bioedit Sequence Alignment Editor (version 7.2.5) was used to alignment and edit the sequence data \[[@b15-kjp-58-1-61]\]. A phylogenetic analysis was performed based on the neighbor-joining methods with a bootstrap value of 1,000 and analyzed using the MEGA (version 6.0) \[[@b16-kjp-58-1-61]\] ([Fig. 3](#f3-kjp-58-1-61){ref-type="fig"}). Sequence genbank enrolled MN515106, MN515108, MN515109, MN518342, MN515138, MN515141, and MN515142 ([Table 1](#t1-kjp-58-1-61){ref-type="table"}).

DNA sequence analysis revealed that one of the patients was infected with *P. ovale curtisi* and 5 were infected with *P. ovale wallikeri*. *P. ovale curtisi* and *P. ovale wallikeri* have been reported previously in Angola, Bangladesh, Equatorial Guinea, Republic of Congo, and Uganda \[[@b17-kjp-58-1-61]\]. The one patient in our study with *P. ovale curtisi* infection (15Po-1) had visited middle Africa (Cameroon). Among the 5 patients with *P. ovale wallikeri* infections, 3 patients with *P. ovale wallikeri* (14Po-1, 15Po-2-1, 15Po-2-2, and 15Po-3) had visited southern Africa (Angola and Zambia). 15Po-2-1 (1,090 bp) and 15Po-2-2 (1,062 bp) have a base sequence difference of 248 bp, and 28 bp are deleted. Therefore, 15Po-2 patients were estimated to be multi-infection. 14Po-1 and 15Po-3 are showed single infection with group A, hwever, 15Po-2 have showed multi-infection with *P. ovale wallikeri* groups A and B, while the other 2 (13Po-1 and 16Po-2) had visited western and eastern Africa (Equatorial Guinea and Uganda) and showed single infection with group B. Although specific country names were not listed, they are quite homologous to those infected and isolated in most West Africa. In this study, the isolated clones were found to be more than 99% consistent with those reported in West Africa. In particular, 15Po-2-1 was found to be 100% consistent ([Fig. 3](#f3-kjp-58-1-61){ref-type="fig"}). Seven 18S rRNA gene variants (GenBank MN515106, MN 515108, MN515109, MN518342, MN515138, MN515141, and MN515142) of *P. ovale curtisi* and *P. ovale wallikeri* were registered in GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>) ([Table 1](#t1-kjp-58-1-61){ref-type="table"}).

*P. ovale* was described in 1922 and was named after the characteristic oval morphology with fimbriated edges of erythrocytes infected with it \[[@b18-kjp-58-1-61]\]. Its morphological resemblance and to *P. vivax* and its tertian periodicity make it easy to be mistaken for *P. vivax* in microscopic analysis \[[@b19-kjp-58-1-61]\]. The incubation period of *P. ovale* has been reported to be 10--17 days \[[@b1-kjp-58-1-61]\]. *P. ovale* is primarily concentrated in sub-Saharan Africa and islands in the western Pacific \[[@b20-kjp-58-1-61]\]. Recently, it was subdivided into 2 genetic types: *P. ovale curtisi* (classic type) and *P. ovale wallikeri* (variant type). Although the 2 types are not morphologically distinguishable through microscopy \[[@b19-kjp-58-1-61]\], their latency periods were reported significantly different; the latency period of *P. ovale curtisi* (85.7 days) is 2 times longer than that of *P. ovale wallikeri* (40.6 days) \[[@b21-kjp-58-1-61]\]. Our epidemiological investigation revealed that latency periods of *P. ovale curtisi* and *P. ovale wallikeri* ranged 149 days and 100.6 days, respectively. Only 1 case (14Po-1) showed 172 days the latency period longer than *P. ovale* curtisi. The latency period was calculated by subtracting the return date from the travel from the date of diagnosis ([Table 1](#t1-kjp-58-1-61){ref-type="table"}). In terms of clinical manifestations, *P. ovale wallikeri* has been reported to cause higher levels of parasitemia and more severe symptoms than *P. ovale curtisi* \[[@b17-kjp-58-1-61]\]. As a result of confirming the parasite count of *P. ovale wallikeri* 2 patients (14Po-1 and 16Po-2), they appeared in 0.62% and 0.67% parasitemia, respectively, and could not be confirmed in the other patients.

All 6 patients reported in this study recovered well. They were treated with chloroquine and primaquine for malaria, and none of them has been diagnoses and treated again because of relapse or drug resistance. To combat the frequent occurrence of imported malaria parasites such as *P. ovale*, rapid and effective PCR-based molecular diagnosis should be performed regularly. Further, routine surveillance of drug susceptibility and resistance among imported malaria parasites will help efforts to effectively eradicate malaria. In particular, molecular monitoring and differential diagnoses such as that for *P. ovale* infection should be routinely performed to understand the multigenic diversities, drug susceptibilities, and drug resistance of malarial parasite.

In conclusion, to the best of our knowledge, this is the first study conducted in the Republic of Korea to report the molecular discrimination between *P. ovale curtisi* and *P. ovale wallikeri*. The low parasite of *P. ovale* and the morphological features similar to *P. vivax* are not easy to differentiate unless a microscopy expert. In addition, *Plasmodium ovale* has low sensitivity in the RDT and is displayed almost in negative. Therefore, after a trip to Africa, PCR must be performed even if malaria is suspected and RDT is negative. The latency period of *P. ovale* infection was found to be similar to that of *P. vivax* infection. *P. ovale* was latent in all patients for at least 30 days, and in some patients, it remained latent for up to 6 months. Thus, it is necessary to epidemiologically assess the latency periods of imported malaria as confirmed in the 6 patients enrolled in this study. Furthermore, travelers who plan to travel to areas endemic for malaria with long latency periods, such as vivax and ovale malaria, will need to take preventive medicines before and after their travels. In the current scenario, owing to the rise in tourism and the associated increase in cases of imported malaria, continuous genetic monitoring would be essential for controlling malaria in the Republic of Korea.
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###### 

Epidemiological factors in 6 cases with *Plasmodium ovale* infection

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Code     Gender   Age   Diagnosis         Travel country   Date of return from travel   Diagnosis date   Latency period (days)   Accession No. (Genbank)   
  ----- -------- -------- ----- ----------------- ---------------- ---------------------------- ---------------- ----------------------- ------------------------- -----------
  1     13Po-1   Male     45    Microscopy, PCR   Pow              Equatorial Guinea            20121009         20130114                97                        MN515106

  2     14Po-1   Male     47    PCR               Pow              Angola                       20131017         20140407                172                       MN515108

  3     15Po-1   Male     25    PCR               Poc              Cameroon                     20140820         20150116                149                       MN515109

  4     15Po-2   Male     36    PCR               Pow              Zambia                       20141028         20150128                92                        MN518342\
                                                                                                                                                                   MN515138

  5     15Po-3   Female   57    PCR               Pow              Zambia                       20150303         20150407                35                        MN515141

  6     16Po-2   Female   45    Microscopy, PCR   Pow              Uganda                       20160814         20161129                107                       MN515142
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Po, *Plasmodium ovale*; Pow, *P. ovale wallikeri*; Poc, *P. ovale curtisi*; PCR, Polymerase Chain Reaction.
